Journal Article

DZNE-2020-04125

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases.

Coll, R. C. ; Robertson, A. A. B. ; Chae, J. J. ; Higgins, S. C. ; Muñoz-Planillo, R. ; Inserra, M. C. ; Vetter, I. ; Dungan, L. S. ; Monks, B. G. ; Stutz, A. ; Croker, D. E. ; Butler, M. S. ; Haneklaus, M. ; Sutton, C. E. ; Núñez, G. ; Latz, E.DZNE* ; Kastner, D. L. ; Mills, K. H. G. ; Masters, S. L. ; Schroder, K. ; Cooper, M. A. (Corresponding author) ; O'Neill, L. A. J.

2015
Nature America Inc. New York, NY

This record in other databases:    

Please use a persistent id in citations: doi:10.1038/nm.3806

Abstract: The NOD-like receptor (NLR) family, pyrin domain-containing protein 3 (NLRP3) inflammasome is a component of the inflammatory process, and its aberrant activation is pathogenic in inherited disorders such as cryopyrin-associated periodic syndrome (CAPS) and complex diseases such as multiple sclerosis, type 2 diabetes, Alzheimer's disease and atherosclerosis. We describe the development of MCC950, a potent, selective, small-molecule inhibitor of NLRP3. MCC950 blocked canonical and noncanonical NLRP3 activation at nanomolar concentrations. MCC950 specifically inhibited activation of NLRP3 but not the AIM2, NLRC4 or NLRP1 inflammasomes. MCC950 reduced interleukin-1β (IL-1β) production in vivo and attenuated the severity of experimental autoimmune encephalomyelitis (EAE), a disease model of multiple sclerosis. Furthermore, MCC950 treatment rescued neonatal lethality in a mouse model of CAPS and was active in ex vivo samples from individuals with Muckle-Wells syndrome. MCC950 is thus a potential therapeutic for NLRP3-associated syndromes, including autoinflammatory and autoimmune diseases, and a tool for further study of the NLRP3 inflammasome in human health and disease.

Keyword(s): Furans (MeSH) ; Animals (MeSH) ; Carrier Proteins: antagonists & inhibitors (MeSH) ; Cryopyrin-Associated Periodic Syndromes: drug therapy (MeSH) ; Disease Models, Animal (MeSH) ; Encephalomyelitis, Autoimmune, Experimental: drug therapy (MeSH) ; Heterocyclic Compounds, 4 or More Rings: pharmacology (MeSH) ; Heterocyclic Compounds, 4 or More Rings: therapeutic use (MeSH) ; Humans (MeSH) ; Inflammasomes: antagonists & inhibitors (MeSH) ; Inflammation (MeSH) ; Interleukin-1beta: drug effects (MeSH) ; Mice (MeSH) ; Multiple Sclerosis (MeSH) ; NLR Family, Pyrin Domain-Containing 3 Protein (MeSH) ; Sulfones: pharmacology (MeSH) ; Sulfones: therapeutic use (MeSH) ; Indenes (MeSH) ; Sulfonamides (MeSH) ; Carrier Proteins ; Heterocyclic Compounds, 4 or More Rings ; IL1B protein, mouse ; Inflammasomes ; Interleukin-1beta ; MCC-950 ; NLR Family, Pyrin Domain-Containing 3 Protein ; NLRP3 protein, human ; Nlrp3 protein, mouse ; Sulfones

---

Contributing Institute(s):

1. Innate Immunity in Neurodegeneration (AG Latz ; AG Latz)

Research Program(s):

1. 342 - Disease Mechanisms and Model Systems (POF3-342) (POF3-342)

Appears in the scientific report 2015

---

Database coverage:
; BIOSIS Previews ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; Ebsco Academic Search ; IF >= 30 ; JCR ; NCBI Molecular Biology Database ; Nationallizenz ; SCOPUS ; Science Citation Index ; Science Citation Index Expanded ; Web of Science Core Collection

---